Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This clinical study is designed as a prospective, open-label, single arm, multicenter study
to evaluate the clinical efficacy and safety of Sintilimab and Nimotuzumab in combination
with chemotherapy in patients with newly diagnosed recurrent/metastatic head and neck
squamous cell carcinoma (R/M HNSCC). The main endpoint is progression free survival (PFS);
the secondary endpoint are objective response rate (ORR), disease control rate (DCR), overall
survival (OS) and safety.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University